ATHENEX INC (ATNX) Stock Price & Overview
NASDAQ:ATNX • US04685N2027
Current stock price
The current stock price of ATNX is 0.2031 USD. Today ATNX is down by -23.39%. In the past month the price decreased by -82.49%. In the past year, price decreased by -97.95%.
ATNX Key Statistics
- Market Cap
- 1.759M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -15.88
- Dividend Yield
- N/A
ATNX Stock Performance
ATNX Stock Chart
ATNX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ATNX. When comparing the yearly performance of all stocks, ATNX is a bad performer in the overall market: 99.85% of all stocks are doing better.
ATNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNX. ATNX has a bad profitability rating. Also its financial health evaluation is rather negative.
ATNX Earnings
ATNX Forecast & Estimates
9 analysts have analysed ATNX and the average price target is 2.3 USD. This implies a price increase of 1029.99% is expected in the next year compared to the current price of 0.2031.
For the next year, analysts expect an EPS growth of 70.35% and a revenue growth -30.28% for ATNX
ATNX Groups
Sector & Classification
ATNX Financial Highlights
Over the last trailing twelve months ATNX reported a non-GAAP Earnings per Share(EPS) of -15.88. The EPS increased by 20.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATNX Ownership
ATNX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.16 | 373.296B | ||
| AMGN | AMGEN INC | 15.3 | 190.378B | ||
| GILD | GILEAD SCIENCES INC | 15.24 | 169.926B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.38 | 115.264B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.85 | 80.002B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.67 | 43.521B | ||
| INSM | INSMED INC | N/A | 31.815B | ||
| BIIB | BIOGEN INC | 11.44 | 28.04B | ||
| NTRA | NATERA INC | N/A | 27.8B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.57 | 23.341B | ||
| MRNA | MODERNA INC | N/A | 21.157B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.471B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATNX
Company Profile
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 269 full-time employees. The company went IPO on 2017-06-14. The firm is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The firm's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.
Company Info
IPO: 2017-06-14
ATHENEX INC
1001 Main St Ste 600
Buffalo NEW YORK 14203 US
CEO: Johnson Y.N. Lau
Employees: 269
Phone: 17168988625.0
ATHENEX INC / ATNX FAQ
What does ATHENEX INC do?
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 269 full-time employees. The company went IPO on 2017-06-14. The firm is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The firm's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.
What is the stock price of ATHENEX INC today?
The current stock price of ATNX is 0.2031 USD. The price decreased by -23.39% in the last trading session.
Does ATNX stock pay dividends?
ATNX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATNX stock?
ATNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is ATHENEX INC (ATNX) expected to grow?
The Revenue of ATHENEX INC (ATNX) is expected to decline by -30.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does ATHENEX INC have?
ATHENEX INC (ATNX) currently has 269 employees.
What is the market capitalization of ATNX stock?
ATHENEX INC (ATNX) has a market capitalization of 1.76M USD. This makes ATNX a Nano Cap stock.